naltrexone for extended release injectable suspension
ApprovedCompleted 0 watching 0 views this week🔥 Hot
82
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Substance-Related Disorders
Conditions
Substance-Related Disorders
Trial Timeline
Mar 1, 2012 → Aug 1, 2015
NCT ID
NCT01563718About naltrexone for extended release injectable suspension
naltrexone for extended release injectable suspension is a approved stage product being developed by Alkermes for Substance-Related Disorders. The current trial status is completed. This product is registered under clinical trial identifier NCT01563718. Target conditions include Substance-Related Disorders.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01563718 | Approved | Completed |
Competing Products
1 competing product in Substance-Related Disorders
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| RDC-0313 + Buprenorphine + Placebo | Alkermes | Phase 1 | 30 |